Skip to main content

Table 3 Characteristics of studies included based on treatment regimens: standard chemotherapy regimen (anthracycline, cyclophosphamide, taxanes) and carboplatin

From: Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis

 

Affiliation

Type of study

Stage of disease

Nº of BRCA1/2 mutated TNBC patients

pCR

Neoadjuvant treatment

Fontaine 2019 [26]

Belgium

RCT phase II

II-III

9

7

Cb-P + E-C

Sella 2018 [35]

Israel

Clinical trial

I-III

14

9

Cb-P-Dox-C

Walsh 2019 [36]

Irland

Retrospective

I-III

6

4

Cb-P + Dox-C

Loib 2018

BrighTNess [37]

USA

RCT phase III

II-III

24

12

Cb-P- Dox-C

  1. pCR Pathological complete response, Cb Carboplatin, Dox Doxorubicin, P Paclitaxel, E Epirubicin, C Cyclophosphamide
Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287